Clinical Trials Browser

Terminated × Neoplasms × ibrutinib × Clear all

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT02973399 2019-02-22

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell